28 results
8-K
EX-10.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
sold by ValenzaBio or its Sub-Licensees to a Third Party customer less [***].
(ii)
The amounts in subsection (i) above shall be determined from … ValenzaBio’s logo for the purpose of naming ValenzaBio as a customer of ProBioGen.
14.5
Use of Cell Lines. ValenzaBio shall refrain from developing new
DEFA14A
ELYM
Eliem Therapeutics Inc
11 Apr 24
Additional proxy soliciting materials
8:10am
at, or to result in, a loss or (ii) for which the customer has already been billed or paid that have not been fully accounted for on the Most Recent Balance Sheet … , employee or representative of any Governmental Entity or of any existing or prospective customer (whether or not owned by a Governmental Entity), (b) any
8-K
EX-2.1
ELYM
Eliem Therapeutics Inc
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
) to perform services or sell products which is expected to be performed at, or to result in, a loss or (ii) for which the customer has already been billed … or prospective customer (whether or not owned by a Governmental Entity), (b) any political party or official thereof, (c) any candidate for political
8-K
EX-10.4
yjzucudcmn 0did
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
10-K
lnrmaaah 16qwb43m
7 Mar 22
Annual report
4:03pm
10-Q
bncibxghg1w7m76f2l
13 Sep 21
Quarterly report
4:01pm
424B4
vyqqf8 cn
11 Aug 21
Prospectus supplement with pricing info
5:05pm